We anticipate there will be some elevation in the burdens, but you want to target that to the right place.
A lot of the activities are occurring, as Dr. Berthiaume has mentioned. Pharmacovigilance planning is an example. We're receiving those now, because they're making them for Europe and the United States, so it's really putting in this structure that gives oversight to those activities. To the extent that many of the activities are occurring, we want to make sure we're getting the proper structure, and that will also affect the assessment of burden.